Feedback
The current prices are delayed. Login to see live prices.
Alembic Pharmaceuticals Ltd.
(APLLTD)
10123456789,201234567891012345678960123456789.3012345678950123456789
+15.40 (+1.28%)
Updated 16:12 26/07 IST
Add
1D
5D
1M
3M
1Y
5Y
MAX
Today's low
₹1,185.45
Today's high
₹1,224.9
52 week low
₹707.15
52 week high
₹1,224.9
Open
₹1,186.1
Prev Close
₹1,200.95
Volume (shares)
477,497
Total Trading Value
57.35 Cr
Technicals
SMA
Value
Signal
12-SMA
1,082.51
Bullish
20-SMA
1,031.23
Bullish
50-SMA
960.58
Bullish
100-SMA
972
Bullish
200-SMA
902.95
Bullish
Valuations
PE Chart
Median PE (M) : 30.57
Current PE is higher than median PE.
PB Chart
Median PB (M) : 3.62
Current PB is higher than median PB.
Fundamentals
Market Cap
₹23,913.44 Cr
Enterprise Value
₹24,217.32 Cr
No. of Shares
19.66 Cr
P/E Ratio(TTM)
38.82
RoE
13.4%
Debt/Equity
0.09
Revenue vs Profitability (In Cr.)
Mar, 2020Mar, 2021Mar, 2022Mar, 2023Mar, 2024
Revenue
Profit
Margins (%)
Mar, 2020Mar, 2021Mar, 2022Mar, 2023Mar, 2024
Gross Margin
Net Margin
Ratios
Debt/Equity
Mar, 2020Mar, 2021Mar, 2022Mar, 2023Mar, 2024
Debt to Equity
ROE vs ROCE
Mar, 2020Mar, 2021Mar, 2022Mar, 2023Mar, 2024
ROE
ROCE
Shareholding
Shareholding Pattern
Public : 10.6%
FII : 4.32%
Others : 0%
DII : 15.47%
Promoter : 69.61%
Shareholding History
Dec, 2022Mar, 2023Jun, 2023Sep, 2023Dec, 2023Jun, 2024
Peer Comparison
Peer companies
Market Capital (Cr.)
P/E
P/B
Price(₹)
SUNPHARMA
411,150.04
42.95
17.36
1,665.8
JBCHEPHARM
29,268.53
52.93
10.14
1,862.75
LAURUSLABS
24,197.47
163.36
5.74
433.85
PFIZER
23,972.96
174.94
6.67
5,285.15
APLLTD
23,933.53
38.82
4.87
1,200.95
NATCOPHARM
23,865.49
17.22
4.27
1,323.8
SUVENPHAR
23,538.35
78.71
11.51
912.45
Discussions
• Just now
USFDA completes inspection at Alembic Pharmaceuticals’ Oral Solid Formulation Facility...read more
• Jul 25 4:48 AM
Alembic Pharmaceuticals gets USFDA’s final nod for Fluphenazine Hydrochloride Tablets...read more
• Jul 21 1:37 AM
• Jul 21 12:59 AM
• Jul 17 9:06 PM
શેર નું નામ :- અલીમ્બિક ફાર્મા
ખરીદારી :- 1081 ...read more
1
1
3
• Jul 13 4:46 AM
Alembic Pharmaceuticals gets USFDA’s tentative nod for Selexipag for Injection
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆...read more
• Jul 11 1:54 AM
• Jul 10 4:46 AM
Alembic Pharma gets USFDA’s final approval for Bromfenac Ophthalmic Solution
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆...read more
• Jul 5 6:02 PM
• Jul 5 4:46 AM
Alembic Pharma gets USFDA’s tentative approval for Ivosidenib Tablets
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆...read more
• Jul 4 8:51 PM
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Alembic Pharmaceuticals has received tentative approva...read more
• Jul 1 8:23 PM
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Alembic Pharmaceuticals has received tentative approva...read more
• Jun 29 4:46 AM
Alembic Pharma gets USFDA’s final nod for Doxycycline Capsules
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆...read more
1
• Jun 19 4:46 AM
Alembic Pharmaceuticals gets USFDA’s nod for Dabigatran Etexilate Capsules
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆...read more
• Jun 18 9:41 PM
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Alembic Pharmaceuticals Ltd. has received final approv...read more
• Jun 18 4:45 AM
Alembic Pharma gets USFDA’s final nod for Icatibant Injection
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆...read more
2
• Jun 17 7:16 PM
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Alembic Pharmaceuticals Ltd. has received final approv...read more
Load More Posts
Frequently Asked Questions (FAQs)
What is the Share Price of Alembic Pharmaceuticals Ltd. ?
The share prices are volatile and fluctuate throughout the trading hours. The share price of Alembic Pharmaceuticals Ltd. is Rs 1200.95 as of 26 July 2024.
What is the Market Capitalization of Alembic Pharmaceuticals Ltd. ?
The current market cap of Alembic Pharmaceuticals Ltd. is ₹23913.44 Cr. Market capitalisation is calculated by multiplying the current share price with the total number of shares.
What are the PE and PB ratios of Alembic Pharmaceuticals Ltd.?
Alembic Pharmaceuticals Ltd. has a price-to-earnings (PE) ratio of 38.82 and a price-to-book (PB) ratio of 4.96.
What is the 52-week high/low of Alembic Pharmaceuticals Ltd.?
The 52-week high of Alembic Pharmaceuticals Ltd. is Rs 1224.9 and the 52-week low is Rs 707.15
Join 10,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
Create your account on Frontpage
FrontPage © 2024